Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.56 |
| ▸ | CA6 | P23280 | 4/20 | 0.56 |
| ▸ | CA4 | P22748 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA7 | P43166 | 4/20 | 0.45 |
| ▸ | CA5A | P35218 | 3/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461558 | 0.81 | RXFP1 (0.50) | LDHACA2CA1CA6CA4 | |
| SCHEMBL2385214 | 0.81 | RXFP1 (0.46) | LDHACA2CA1CA6CA4 | |
| SCHEMBL30987398 | 0.81 | RXFP1 (0.46) | LDHACA2CA1CA6CA4 | |
| SCHEMBL3578778 | 0.81 | FABP4 (0.51) | LDHACA2CA1CA6CA4 | |
| Serine SCHEMBL28354203 | 0.80 | LDHA (0.47) | LDHACA2CA1CA6CA4 | |
| SCHEMBL6614757 | 0.79 | FABP4 (0.50) | LDHACA2CA1CA6CA4 | |
| Potassium Ion SCHEMBL6614753 | 0.79 | RXFP1 (0.45) | LDHACA2CA1CA6CA4 | |
| SCHEMBL9138970 | 0.79 | CDK2 (0.78) | LDHACA2CA1CA6CA4 | |
| SCHEMBL108422 | 0.78 | LDHA (0.64) | LDHACA2CA1CA6CA4 | |
| SCHEMBL1805457 | 0.78 | LDHA (1.00) | LDHACA2CA1CA6CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133292-A1 | NOVEL CCR8 ANTAGONISTS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | SRX CARDIO, LLC | 2021-02-04 | — | — | US | disclosed |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | SRX CARDIO, LLC | 2021-02-04 | — | — | US | disclosed |
| WO-2019178383-A1 | INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF | VANDERBILT UNIVERSITY (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2019-04-25 | — | — | US | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | disclosed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | disclosed |
| CN-102617259-B | Method for synthesizing amine compounds through alcohol and amine dehydration | UNIV WENZHOU | 2014-12-24 | — | — | CN | disclosed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| CN-102617259-A | Method for synthesizing amine compounds through alcohol and amine dehydration | UNIV WENZHOU | 2012-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | LDHA 3912/4885CA2 4275/4885CA1 4333/4885 |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | LDHA 422/4885CA2 341/4885CA1 1091/4885 |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | PCSK9, PCSK6, PCSK7 | LDHA 3745/4885CA2 4368/4885CA1 4296/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | LDHA 3346/4885CA2 4122/4885CA1 4708/4885 |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | LDHA 3518/4885CA2 4244/4885CA1 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.